KPMG
Ogletree Deakins and KPMG Law in Germany1 are forming a global alliance to provide businesses with global workforce solutions. This alliance will be instrumental in expanding immigration and employment law reach for both organizations and will enable KPMG firms outside of the US2 to bring the US capability and services of Ogletree Deakins to their clients around the world.
The alliance is in response to growing client demand for a technology-powered, globally unified approach to business challenges faced in the areas of immigration and global mobility, labor and employment, and the associated tax, compensation, and benefits issues. This non-exclusive alliance with Ogletree Deakins does not include KPMG in the US or entities that it owns or controls, which do not provide legal services3 .
“As businesses expand and look to shore up recovery in the post-pandemic world, there is increasing pressure for multinational organizations seeking to get the right people in the right places at the right time, and in compliance with the requirements of any given jurisdiction,” said Thomas Wolf , Head of Global Immigration Services for the KPMG organization. “Ogletree Deakins’ labor, employment and immigration experience in the United States is a perfect fit for KPMG’s organization of firms as we expand our global legal services practice4 and our global mobility services offerings around the world. We are excited to join forces with Ogletree Deakins to offer clients even deeper global coverage for their pressing employment and immigration legal matters.”
Both Ogletree Deakins and KPMG Law in Germany are leaders in utilizing technology and innovation to enhance client service, including in the areas of artificial intelligence, data analytics and knowledge management. By combining the strengths of both organizations, this new alliance will provide clients with an increased breadth of technology solutions. KPMG Law in Germany is part of the broader KPMG Law / Global Legal Services network across KPMG firms, with 2,800 lawyers in 81 jurisdictions.
“Ogletree Deakins is an international labor and employment firm and has established an extensive network of lawyers practicing in 53 offices across North America and in Europe to meet our clients’ needs. Our alliance with KPMG Law in Germany will benefit clients by complementing our US labor, employment and immigration offerings with ‘end-to-end’ workplace solutions—including tax, compensation, global immigration, and related advisory and consulting services, over a truly global footprint. Our firm shares a vision with the KPMG network for client service, innovation and cutting-edge technology solutions, and we are already working together on a next generation mobility services platform,” said Matt Keen , managing shareholder of Ogletree Deakins.
About Ogletree Deakins
Ogletree Deakins is one of the largest US labor and employment law firms representing management in all types of employment-related legal matters. Premier client service, as outlined in the firm’s Client Pledge, is one of the firm’s top priorities and a cornerstone of its core values. U.S. News – Best Lawyers® “Best Law Firms” has named Ogletree Deakins a “Law Firm of the Year” for 10 consecutive years. In 2021, the publication named Ogletree Deakins its “Law Firm of the Year” in the Litigation – Labor & Employment category. Ogletree Deakins has more than 900 attorneys located in 53 offices across the United States and in Europe, Canada, and Mexico. The firm represents a diverse range of clients, from small businesses to Fortune 50 companies. More: ogletree.com.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 146 countries and territories and in FY20 had close to 227,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. More: kpmg.com
_______________________________
1 The agreement will be initially signed by KPMG Law Rechtsanwaltsgesellschaft mbH (“KPMG Law in Germany”), which is associated with KPMG AG Wirtschaftsprüfungsgesellschaft, the German member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. Other non-US member firms are expected to join this non-exclusive alliance over the next several months.
2 KPMG Law in Germany was established in 2007 and is an independent corporate law firm associated with KPMG AG Wirtschaftsprüfungsgesellschaft and affiliated with the KPMG International Cooperative. This non-exclusive alliance with Ogletree Deakins does not include the KPMG US member firm or entities that it owns, or controls, which do not provide legal services. For cases where KPMG in the US clients require immigration and/or employment and labor law services, Ogletree Deakins may contract with these clients separately.
3 For cases where KPMG US clients require immigration and/or employment and labor law services, Ogletree Deakins would contract with these clients separately.
4 Certain member firms of the KPMG global organization, including KPMG in the US, do not provide legal services. For the purpose of this press release any commentary will be on general concepts only and is not in any way intended as legal advice or views on laws of any jurisdiction.
Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates and related entities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210509005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom